Ascendis Pharma A/S - ADR
ASND
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
27.1% downsideOvervalued by 27.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.85 Billion |
|---|---|
| Enterprise Value | $14.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.62 |
| Beta | 0.41 |
| Outstanding Shares | 61,681,886 |
Return
| Return on Equity | 103.71% |
|---|---|
| Return on Assets | 25.26% |
| Return on Invested Capital | -2.77% |
Valuation & Multiples
| P/E Ratio | 23.4 |
|---|---|
| PEG | -3.02 |
| Price to Sales | 15.49 |
| Price to Book Ratio | 30.97 |
| Enterprise Value to Revenue | 16.34 |
| Enterprise Value to EBIT | -582.43 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 1.85 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1628▼ 12.48% |
|---|---|
| Total Calls | 1,271,837▲ 55.48% |
| Total Puts | 207,100▼ 11.98% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.14%▼ 16.91% |
|---|---|
| Total Invested | $12.50B▼ 9.27% |
| Investors Holding | 289▼ 38.00% |
ESG Score
No data
About Ascendis Pharma A/S
CEO: Jan Moeller Mikkelsen Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy, which dictates the commercial viability and pricing of new pharmaceutical products.
Allocates funding for the FDA and NIH, directly impacting the speed of regulatory reviews and the volume of federal medical research.
Directly oversees the FDA and the drug approval process, critical for a company with pending clinical data and new drug applications.
Central to patent law and intellectual property protection, which are fundamental to the valuation of pharma pipelines.